All In Biotech

Drug Trial Radar · NCT04995523

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

212

Actual

Start

Sep 14, 2021

Primary completion

Jun 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

  • AZD2936Drug

    Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parametersTime frame: Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
  2. Rate of rilvegostomig discontinuation due to toxicityTime frame: Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
  3. Objective Response Rate (ORR)Time frame: Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)

Locations

40 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Chicago, Illinois

  • Research Site

    Rochester, Minnesota

  • Research Site

    Fairfax, Virginia

  • Research Site

    Melbourne, Australia

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Natal, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Dijon, France

  • Research Site

    Toulouse, France

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Kashiwa, Japan

  • Research Site

    Niigata, Japan

  • Research Site

    Sendai, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Kuala Lumpur, Malaysia

  • Research Site

    Kuching, Malaysia

  • Research Site

    Chisinau, Moldova

  • Research Site

    Groningen, Netherlands

  • Research Site

    Leiden, Netherlands

  • Research Site

    Utrecht, Netherlands

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Taichung, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Bangkok, Thailand

  • Research Site

    Chanthaburi, Thailand

  • Research Site

    Muang, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.